Avoid common mistakes on your manuscript.
Sarcopenia is defined by the European Working Group on Sarcopenia in Older People 2 (EWGSOP2) as progressive and generalized skeletal muscle degeneration with reduction in muscle strength, quality, and/or performance [1], which is further classified according to etiology into primary (attributed to the aging process) or secondary (caused by cytokine-mediated inflammation in chronic diseases such as cancer, endocrine disease, or organ failure) [2]. Sarcopenia in cancer patients is associated with lower survival and worse tolerance to chemotherapeutic agents [2,3,4,5,6]. The standard radiological method to estimate sarcopenia is to measure skeletal muscle mass at the level of the third lumbar vertebral body (L3) on axial computed tomography (CT) images using either manual or deep learning automated segmentation [7,8,9,10,11]. Software packages frequently provide measurements of visceral and subcutaneous fat as well.
In the article recently published in European Radiology by Surov et al [12], the authors investigated the predictive value of skeletal muscle mass (SMM) for dose-limited toxicity (DLT) and survival in patients suffering from primary CNS lymphoma. They found a higher objective response rate (ORR) in patients with higher muscle density. In other words, sarcopenia was associated with poor ORR. The authors used freely available software to measure skeletal muscle area (SMA), skeletal muscle index (SMI), visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT), and visceral to subcutaneous adipose ratio (VSR) [12]. Measurements were done utilizing pre-defined HU thresholds (− 190 to − 30 to define fat and − 29 to 150 to define muscles) on post-contrast (portal phase) axial CT images at mid L3. Although this method does not require precise training or long post-processing times, it requires post-contrast CT scans of the abdomen, which might not be routine for patients with CNS lymphoma given that PET has a higher diagnostic yield than CT [13]. Another limitation is that routine measurements of sarcopenia are performed on non-contrast images to avoid contrast-related changes in muscle density (HU), which may in turn affect the definition of tissues that was performed using pre-defined HU (as mentioned earlier). The authors of this article claim that the area of adipose tissue and muscle would not be affected [12]. Finally, the researchers choose to define complete/partial response or progressive/stable disease based on the size of enhancing lesions. Complete response (CR) was defined as complete disappearance of contrast enhancement on MRI. Partial response (PR) was defined as a 50% decrease in enhancing tumor diameters. Progressive disease (PD) was defined as a 25% increase in the enhancing lesions or the appearance of any new CNS or non-CNS site of disease. Any other situation was characterized as stable disease (SD). Although this method is widely applied, new consensus recommendations are to use volumetric measurements combined with functional data from DWI, perfusion MRI, and PET for systemic staging evaluation in clinical practice and clinical trials [14].
Those limitations aside, the main strength of this study is that it shows a strong association between low skeletal muscle mass (LSMM) and objective response rate, which may have clinical implications around patient selection for treatments and trials and for inclusion oncology nutritionists in the PCNS lymphoma treatment team.
References
Cruz-Jentoft AJ, Bahat G, Bauer J et al (2019) Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 48:16–31
Roubenoff R, Parise H, Payette HA et al (2003) Cytokines, insulin-like growth factor 1, sarcopenia, and mortality in very old community-dwelling men and women: the Framingham Heart Study. Am J Med 115:429–435
Vashi PG, Gorsuch K, Wan L, Hill D, Block C, Gupta D (2019) Sarcopenia supersedes subjective global assessment as a predictor of survival in colorectal cancer. PLoS One 14:e0218761
Chargi N, Bril SI, Emmelot-Vonk MH, de Bree R (2019) Sarcopenia is a prognostic factor for overall survival in elderly patients with head-and-neck cancer. Eur Arch Otorhinolaryngol 276:1475–1486
Anjanappa M, Corden M, Green A et al (2020) Sarcopenia in cancer: risking more than muscle loss. Tech Innov Patient Support Radiat Oncol 16:50–57
Fukushima H, Koga F (2017) Impact of sarcopenia in the management of urological cancer patients. Expert Rev Anticancer Ther 17:455–466
Zopfs D, Theurich S, Große Hokamp N et al (2020) Single-slice CT measurements allow for accurate assessment of sarcopenia and body composition. Eur Radiol 30:1701–1708
Green A, Cipriano C, Osorio E, Weaver J, Van Herk M, McWilliam A (2019) PO-0960 Automated sarcopenia assessment and its predictive power in lung cancer radiotherapy patients. Radiother Oncol 133:S521
Dabiri S, Popuri K, Cespedes Feliciano EM, Caan BJ, Baracos VE, Beg MF (2019) Muscle segmentation in axial computed tomography (CT) images at the lumbar (L3) and thoracic (T4) levels for body composition analysis. Comput Med Imaging Graph 75:47–55
Ní Bhuachalla ÉB, Daly LE, Power DG, Cushen SJ, MacEneaney P, Ryan AM (2018) Computed tomography diagnosed cachexia and sarcopenia in 725 oncology patients: is nutritional screening capturing hidden malnutrition? J Cachexia Sarcopenia Muscle 9:295–305
Tagliafico AS, Bignotti B, Torri L, Rossi F (2022) Sarcopenia: how to measure, when and why. Radiol Med 127:228–237
Surov A, Meyer HJ, Hinnerichs M et al (2023) CT-defined sarcopenia predicts treatment response in primary central nervous system lymphomas. Eur Radiol. https://doi.org/10.1007/s00330-023-09712-y
Usman S, Jain A, Riyami KA, Naumani SP, Sukaiti RA, Shamim MS (2023) The role of 18F-FDG PET/CT in evaluation of primary CNS lymphoma: the path less travelled. J Pak Med Assoc 73:1744–1746
Barajas RF, Politi LS, Anzalone N et al (2021) Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG). Neuro Oncol 23:1056–1071
Funding
The author states that this work has not received any funding.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Guarantor
The scientific guarantor of this publication is Lamiaa el-Sorogy.
Conflict of interest
The author of this manuscript declares no relationships with any companies, whose products or services may be related to the subject matter of the article.
Statistics and biometry
No complex statistical methods were necessary for this paper.
Informed consent
Written informed consent was not required.
Ethical approval
Institutional Review Board approval was not required.
Study subjects or cohorts overlap
N/A
Methodology
• commentary
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This comment refers to the article available at https://doi.org/10.1007/s00330-023-09712-y.
Rights and permissions
About this article
Cite this article
Fahmy, D.M. Might sarcopenia be patient-oriented evidence that matters in CNS lymphomas? A glance out of the neuraxis. Eur Radiol 34, 788–789 (2024). https://doi.org/10.1007/s00330-023-10512-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00330-023-10512-7